ADAPTIVE BIOTECHNOLOGIES CORPORATION Operating Lease, Liability, Noncurrent
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Operating Lease, Liability, Noncurrent of $66.80 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability, Noncurrent $66.80M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $69.11M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $70.23M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $72.36M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $66.80M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $69.11M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $70.23M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $72.36M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $74.41M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $76.44M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $79.15M 10-K · filed 2026-02-26 |
| 2024-09-30 | $81.80M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $84.37M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $86.90M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $89.39M 10-K · filed 2025-03-03 |
| 2023-09-30 | $91.82M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $94.18M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $96.49M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $98.77M 10-K · filed 2024-02-29 |
| 2022-09-30 | $100.52M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $102.73M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $104.98M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $106.69M 10-K · filed 2023-02-14 |
| 2021-09-30 | $108.04M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $103.77M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $95.25M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $104.33M 10-K · filed 2022-02-15 |
| 2020-09-30 | $42.37M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $42.50M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $36.55M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |